StageZero Life Sciences Ltd. (OTCMKTS:GNWSF – Get Free Report)’s share price traded up 31% during mid-day trading on Wednesday . The stock traded as high as $0.12 and last traded at $0.12. 28,487 shares were traded during trading, an increase of 7% from the average session volume of 26,719 shares. The stock had previously closed at $0.09.
StageZero Life Sciences Trading Up 31.0 %
The firm has a market cap of $7.56 million, a PE ratio of -0.43 and a beta of 0.28. The business’s 50-day simple moving average is $0.06 and its 200 day simple moving average is $0.03.
StageZero Life Sciences Company Profile
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood.
Featured Stories
- Five stocks we like better than StageZero Life Sciences
- What Are Some of the Best Large-Cap Stocks to Buy?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- The Role Economic Reports Play in a Successful Investment Strategy
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
